Австралія - англійська - Department of Health (Therapeutic Goods Administration)

novotech australia pty ltd - simvastatin -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 40 mg/ml - oral liquid - excipient ingredients: purified water; sorbitol solution (70 per cent) (non-crystallising); sodium methyl hydroxybenzoate; citric acid; brilliant scarlet 4r; hyetellose; sodium propyl hydroxybenzoate; saccharin sodium; flavour - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - vancomycin hydrochloride, quantity: 128 mg (equivalent: vancomycin, qty 125 mg) - capsule - excipient ingredients: iron oxide red; gelatin; indigo carmine; titanium dioxide; macrogol 6000; iron oxide yellow - this product accepted for registration as 'currently supplied' at the time of commencement of the act. revisions of product information was approved as specified in the letter of 13 august 1992 from dr alex proudfoot advising of approval for registration of the goods. indicated for the treatment of staphylococcal enterocolitis and antibiotic - associated pseudomembranous colitis produced by c. difficile.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - vancomycin hydrochloride, quantity: 256 mg (equivalent: vancomycin, qty 250 mg) - capsule - excipient ingredients: iron oxide black; titanium dioxide; indigo carmine; iron oxide red; gelatin; macrogol 6000 - this product accepted for registration as 'currently supplied' at the time of commencement of the act. revision of product information was approved as specified in the letter of 13 august 1992 from dr alex proudfoot advising of approval for registration of the goods. indicated for staphylococcal enterocolitis and antibiotic - associated pseudomembranous colitis produced by c. difficile.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - azathioprine, quantity: 50 mg - injection, powder for - excipient ingredients: sodium hydroxide - indications as at 11 february 2005: imuran is used as an immunosuppressant antimetabolite either alone, or more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. imuran, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. imuran, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering form the following: severe rheumatoid arthritis; systemic lupus erythematosus; dermatomyositis/polymyositis; autoimmune chronic active hepatitis; pemphigus vulgaris; polya

Австралія - англійська - APVMA (Australian Pesticides and Veterinary Medicines Authority)

arysta lifescience australia pty ltd - fluroxypyr as the methyl heptyl ester; liquid hydrocarbon - emulsifiable concentrate - fluroxypyr as the methyl heptyl ester pyridine-pyridinoxy active 200.0 g/l; liquid hydrocarbon solvent other 586.0 g/l - herbicide - aerial spraying | agricultural non-crop areas | basal bark | broadcast application | commercial/industrial land | forest | grass - amaranth or amaranthus | annual ground cherry | anoda weed | apple-of-peru | balsam pear | bathurst burr | bedstraw | bellvine | bellyache bush | bittercress or swinecress | black bindweed | black nightshade | blackberry nightshade | bladder ketmia | blue billygoat weed | blue heliotrope or blue top | boggabri weed | bokhara clover | broadleaf pepper tree | caltrop or yellow vine | centro | chinee apple | chinese celtis | cleavers | cobbler's pegs | cockspur thorn | common sensitive plant | cowpea | cowvine | deadnettle | dock | dwarf amaranth or boggabri weed | flannel weed | fumitory | giant or black pigweed | giant sensitive plant | green amaranth | hairy wandering jew | honey locust | lablab bean | lantana spp. | limebush | madeira vine | marsh or smallflower mallow | melilotus or hexham scent | milkweed | mimosa bush | mimosa pigra | mintweed | mistflower or creeping crofton weed | morning glory - ipomoea spp. | mother-of-millions | mustard | noogoora burr | perennial ground cherry | perennial pigweed |

Австралія - англійська - APVMA (Australian Pesticides and Veterinary Medicines Authority)

fmc australasia pty ltd - fluroxypyr as the methyl heptyl ester; n-methylpyrrolidone; liquid hydrocarbon - emulsifiable concentrate - fluroxypyr as the methyl heptyl ester pyridine-pyridinoxy active 400.0 g/l; n-methylpyrrolidone solvent other 100.0 g/l; liquid hydrocarbon solvent other 299.0 g/l - herbicide - agricultural non-crop areas | commercial/industrial land | forest | grass pasture - established (see label) | lucerne - establis - amaranth or amaranthus | annual ground cherry | anoda weed | apple-of-peru | balsam pear | bathurst burr | bedstraw | bellvine | bellyache bush | black bindweed | black or brisbane black wattle | blackberry nightshade | bladder ketmia | blue billygoat weed | blue heliotrope or blue top | bokhara clover | brigalow | broadleaf pepper tree | brown salwood or hickory wattle | caltrop or yellow vine | centro | chinee apple | chinese celtis | cleavers | cobbler's pegs | cockspur thorn | common pigweed | common sensitive plant | cooba | cowpea | cowvine | deadnettle | dock | dwarf amaranth or boggabri weed | fumitory | giant or black pigweed | giant sensitive plant | green amaranth | hairy wandering jew | honey locust | lablab bean | lantana spp. | lesser swinecress or bittercress | limebush | madeira vine | melilotus or hexham scent | milkweed | mimosa bush | mimosa pigra | mintweed | mistflower or creeping crofton weed | morning glory - ipomoea spp. | mother-of-millions | mustard | noogoora burr | perennial ground

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - bosentan monohydrate, quantity: 129.082 mg - tablet, film coated - excipient ingredients: maize starch; pregelatinised maize starch; sodium starch glycollate type a; povidone; glycerol dibehenate; magnesium stearate; hypromellose; titanium dioxide; triacetin; purified talc; iron oxide yellow; iron oxide red; ethylcellulose; cetyl alcohol; sodium lauryl sulfate - for the treatment of ? idiopathic pulmonary arterial hypertension ? familial pulmonary arterial hypertension ? pulmonary arterial hypertension associated with scleroderma or ? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - bosentan monohydrate, quantity: 64.541 mg - tablet, film coated - excipient ingredients: maize starch; pregelatinised maize starch; sodium starch glycollate type a; povidone; glycerol dibehenate; magnesium stearate; hypromellose; titanium dioxide; triacetin; purified talc; iron oxide yellow; iron oxide red; ethylcellulose; cetyl alcohol; sodium lauryl sulfate - for the treatment of ? idiopathic pulmonary arterial hypertension ? familial pulmonary arterial hypertension ? pulmonary arterial hypertension associated with scleroderma or ? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alirocumab, quantity: 150 mg - injection, solution - excipient ingredients: histidine; sucrose; polysorbate 20; water for injections - primary hypercholesterolaemia praluent is indicated as an adjunct to diet and exercise to reduce ldl-c in adults with primary (heterozygous familial or non-familial) hypercholesterolaemia in patients with moderate to very high cardiovascular risk: - in combination with a statin, or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with maximum tolerated dose of a statin, - alone or in combination with other lipid lowering therapies in patients who are statin intolerant or for whom a statin is contraindicated who are unable to reach ldl-c goals. praluent-ccdsv12-piv9-d3-30sep22 page 2 of 35 prevention of cardiovascular events praluent is indicated to reduce the risk of cardiovascular events (myocardial infarction, stroke, unstable angina requiring hospitalisation) in adults with established cardiovascular disease, in combination with optimally dosed statins and/or other lipid-lowering therapies (see section 5.1 pharmacodynamic properties, clinical trials).